Potential of old-generation antibiotics to address current need for new antibiotics

References

• Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis.46(2), 155–164 (2008).
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. Bad Bugs, No drugs. As Antibiotic Discovery Stagnates, a Public Health Crisis Brews. Infectious Diseases Society of America (Eds). Alexandria, VA, USA (2004).
   Google Scholar
• Projan SJ. Why is Big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol.6(5), 427–430 (2003).
   PubMed Web of Science ®Google Scholar
• Bradley JS, Guidos R, Baragona S et al. Anti-infective research and development – problems, challenges, and solutions. Lancet Infect. Dis.7(1), 68–78 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis.5(1), 24 (2005).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol.55(Pt 12), 1619–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Livermore DM. The need for new antibiotics. Clin. Microbiol. Infect.10(Suppl. 4), 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karveli EA, Siempos, II, Vardakas KZ. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol. Infect.136(8), 1009–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis.34(5), 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest129(6), 1432–1440 (2006).
   PubMed Web of Science ®Google Scholar
• Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit. Care Med.34(1), 15–21 (2006).
   PubMed Web of Science ®Google Scholar
• Malacarne P, Langer M, Nascimben E et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit. Care Med.36(4), 1105–1113 (2008).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Stavridis G, Geroulanos S. Severe sepsis in cardiac surgical patients. Eur. J. Surg.164(3), 217–222 (1998).
   PubMedGoogle Scholar
• Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis.5(2), 115–119 (2005).
   PubMed Web of Science ®Google Scholar
• Pelaez F. The historical delivery of antibiotics from microbial natural products – can history repeat? Biochem. Pharmacol.71(7), 981–990 (2006).
   PubMed Web of Science ®Google Scholar
• Weber T, Welzel K, Pelzer S, Vente A, Wohlleben W. Exploiting the genetic potential of polyketide producing streptomycetes. J. Biotechnol.106(2–3), 221–232 (2003).
   PubMed Web of Science ®Google Scholar
• Baltz RH. Genetic manipulation of antibiotic-producing Streptomyces. Trends Microbiol.6(2), 76–83 (1998).
   PubMed Web of Science ®Google Scholar
• Pucci MJ. Use of genomics to select antibacterial targets. Biochem. Pharmacol.71(7), 1066–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Monaghan RL, Barrett JF. Antibacterial drug discovery – then, now and the genomics future. Biochem. Pharmacol.71(7), 901–909 (2006).
   PubMed Web of Science ®Google Scholar
• Overbye KM, Barrett JF. Antibiotics: where did we go wrong? Drug Discov. Today10(1), 45–52 (2005).
   PubMed Web of Science ®Google Scholar
• Butler MS, Buss AD. Natural products – the future scaffolds for novel antibiotics? Biochem. Pharmacol.71(7), 919–929 (2006).
   PubMed Web of Science ®Google Scholar
• Coates AR, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br. J. Pharmacol.152(8), 1147–1154 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Fragoulis KN, Karydis I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE1, E11 (2006).
   PubMedGoogle Scholar
• Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov. Today5(7), 294–300 (2000).
   PubMed Web of Science ®Google Scholar
• Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat. Biotechnol.24(12), 1541–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Yim G, Wang HH, Davies J. The truth about antibiotics. Int. J. Med. Microbiol.296(2–3), 163–170 (2006).
   PubMed Web of Science ®Google Scholar
• Yim G, Wang HH, Davies J. Antibiotics as signalling molecules. Philos. Trans. R. Soc. Lond. B Biol. Sci.362(1483), 1195–1200 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr. Opin. Crit. Care13(5), 592–597 (2007).
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococci. Am. J. Med.102(3), 284–293 (1997).
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case–control study. Crit. Care Med.36(3), 807–811 (2008).
   PubMed Web of Science ®Google Scholar
• Rolinson GN. The history and background of augmentin. S. Afr. Med. J.62(5 Spec.), A3–A4 (1982).
   Web of Science ®Google Scholar
• Merz LR, Warren DK, Kollef MH, Fraser VJ. Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Antimicrob. Agents Chemother.48(8), 2861–2865 (2004).
   PubMed Web of Science ®Google Scholar
• Pechere JC. Rotating antibiotics in the intensive care unit: feasible, apparently beneficial, but questions remain. Crit. Care6(1), 9–10 (2002).
   PubMed Web of Science ®Google Scholar
• Warren DK, Hill HA, Merz LR et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit. Care Med.32(12), 2450–2456 (2004).
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother.61(3), 636–642 (2008).
   PubMed Web of Science ®Google Scholar
• Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis.45(6), 753–760 (2007).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Metaanalysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis. Pediatr. Infect. Dis. J.24(10), 909–917 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs68(13), 1841–1854 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kazantzi MS, Bliziotis IA. Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. J. Med. Microbiol.57(Pt 1), 1–8 (2008).
   PubMed Web of Science ®Google Scholar
• Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int. J. Antimicrob. Agents21(6), 521–524 (2003).
   PubMed Web of Science ®Google Scholar
• Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim–sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med.117(5), 390–398 (1992).
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother.49(8), 3136–3146 (2005).
   PubMed Web of Science ®Google Scholar
• Stein A, Raoult D. Colistin: an antimicrobial for the 21st Century? Clin. Infect. Dis.35(7), 901–902 (2002).
   PubMed Web of Science ®Google Scholar
• Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin. Infect. Dis.43(Suppl. 2), S89–S94 (2006).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care10(1), R27 (2006).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med.102(3), 407–412 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol.39(1), 15–20 (2005).
   PubMed Web of Science ®Google Scholar
• Etherington C, Bosomworth M, Clifton I, Peckham DG, Conway SP. Measurement of urinary N-acetyl-β-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J. Cyst. Fibros.6(1), 67–73 (2007).
   PubMed Web of Science ®Google Scholar
• Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol.71(7), 968–980 (2006).
   PubMed Web of Science ®Google Scholar
• Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J. Antimicrob. Chemother.55(Suppl. 2), ii5–ii13 (2005).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis.46(7), 1069–1077 (2008).
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Chua JD, Tuohy MJ et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand. J. Infect. Dis.35(1), 12–14 (2003).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis.27(6), 439–443 (2008).
   PubMed Web of Science ®Google Scholar
• Nissen LR, Jacobsen J, Ravn TJ, Wahlgreen C, Auning-Hansen H. Fosfomycin–ampicillin versus gentamicin–ampicillin in the treatment of critically ill patients with pneumonia. Infection14(5), 246–249 (1986).
   PubMed Web of Science ®Google Scholar
• Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern. Med. J.35(Suppl. 2), S3–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Howden BP, Grayson ML. Dumb and dumber – the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis.42(3), 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• Jemni L, Hmouda H, Letaief A. Efficacy of trimethoprim–sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia. Clin. Infect. Dis.19(1), 202–203 (1994).
   PubMed Web of Science ®Google Scholar
• Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim–sulfamethoxazole). Antimicrob. Agents Chemother.42(12), 3086–3091 (1998).
   PubMed Web of Science ®Google Scholar
• Huovinen P. Resistance to trimethoprim–sulfamethoxazole. Clin. Infect. Dis.32(11), 1608–1614 (2001).
   PubMed Web of Science ®Google Scholar
• Bishara J, Pitlik S, Samra Z, Levy I, Paul M, Leibovici L. Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988–1997. Emerg. Infect. Dis.9(9), 1168–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Nimmo GR, Bell JM, Mitchell D, Gosbell IB, Pearman JW, Turnidge JD. Antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals, 1989–1999. Microb. Drug Resist.9(2), 155–160 (2003).
   PubMed Web of Science ®Google Scholar
• Udo EE, Al-Sweih N, Mokaddas E et al. Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994–2004. BMC Infect. Dis.6, 168 (2006).
   PubMed Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J. Antimicrob. Chemother.56(3), 470–480 (2005).
   PubMed Web of Science ®Google Scholar
• Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol.1(5), 464–469 (2001).
   PubMedGoogle Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother.56(4), 611–614 (2005).
   PubMed Web of Science ®Google Scholar
• Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updat.5(3–4), 119–125 (2002).
   PubMed Web of Science ®Google Scholar
• Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br. J. Clin. Pharmacol.39(6), 597–603 (1995).
   PubMed Web of Science ®Google Scholar
• Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol.5(6), 234–240 (1997).
   PubMed Web of Science ®Google Scholar
• Beauchamp D, Labrecque G. Chronobiology and chronotoxicology of antibiotics and aminoglycosides. Adv. Drug Deliv. Rev.59(9–10), 896–903 (2007).
   PubMed Web of Science ®Google Scholar
• Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. J. Microbiol. Immunol. Infect.40(6), 481–486 (2007).
   PubMedGoogle Scholar